$KITE Form 8-K


Form 8-K for KITE PHARMA, INC.


Other Events, Financial Statements and Exhibits

Item 8.01 Other Events.On August 17, 2015, Kite Pharma, Inc. issued a press release announcing an update on its multicenter Phase 1-2 clinical trial for its lead product candidate KTE-C19, a chimeric antigen receptor-based therapy, in patients with refractory diffuse large B cell lymphoma, including primary mediastinal B cell lymphoma and transformed follicular lymphoma. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.


Item 9.01 Financial Statements and Exhibits.(d) Exhibits.

The following exhibit is filed as part of this Current Report:

99.1 Press Release of Kite Pharma, Inc. issued August 17, 2015.


Please enter your comment!
Please enter your name here